COVID-19

COVID-19: What you need to know about the coronavirus pandemic on 27 November

A balloon is seen during the 94th Macy's Thanksgiving Day Parade closed to the spectators due to the spread of the coronavirus disease (COVID-19), in Manhattan, New York City, U.S., November 26, 2020. REUTERS/Andrew Kelly - RC22BK9EY8XS

New York's traditional Thanksgiving Day parade looked very different this year. Image: REUTERS/Andrew Kelly

Joe Myers
Writer, Forum Agenda
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on COVID-19?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

COVID-19

  • This daily round-up brings you a selection of the latest news and updates on the COVID-19 coronavirus pandemic, as well as tips and tools to help you stay informed and protected.
  • Top stories: Britain asks regulator to assess Oxford/AstraZeneca vaccine; WHO's Ryan says vaccine offers chance to gain progressive control; Berlin plans mass vaccination centres.
Have you read?

1. How COVID-19 is affecting the globe

Confirmed cases of COVID-19 have now passed 61 million globally, according to the Johns Hopkins Coronavirus Resource Center. The number of confirmed deaths stands at more than 1.43 million.

South Korea has reported more than 500 new COVID-19 cases for a second consecutive day – levels not seen in nearly nine months.

Ireland is set to reopen pubs and restaurants on 7 December. They were closed on 21 October, when the government shut all non-essential retail, and pubs and restaurants were limited to takeaway service.

Daily new confirmed COVID-19 cases per million people in selected countries
Ireland's cases have been lower than many of its immediate European neighbours. Image: Our World in Data

Berlin is planning to open six mass vaccination centres, capable of handling up to 4,000 people per day by mid-December.

New post-lockdown tiers have been announced for England, with 20 million people set to be under the toughest level of restrictions.

The European Central Bank must keep borrowing costs low to allow governments to spend their way out of a pandemic-induced recession, ECB board member Fabio Panetta told a Portuguese newspaper.

Australia's second largest state, Victoria, once the country's coronavirus hotspot, has now gone 28 days without detecting any new infections.

2. The potential impact of a vaccine

The introduction of a COVID-19 vaccine should allow the world to gain control over the disease next year, Dr Mike Ryan, the Executive Director of the World Health Organization's Health Emergencies Programme, told Irish TV.

“Life as we used to know it, I think that’s very, very possible but we will have to continue with the hygiene, physical distancing. Vaccines do not equal zero COVID. Adding vaccines to our current measures will allow us to really crush the curve, avoid lockdowns and gain progressive control over the disease,” he said.

Discover

What is the World Economic Forum doing about access to vaccines?

But he warned about the potential impact of Christmas.

“We need to be absolutely aware that we need to reduce the chance that we could infect someone else in just organising households carefully around the Christmas festivities."

3. Britain asks regulator to assess Oxford/AstraZeneca vaccine

Britain has asked its medical regulator to assess the COVID-19 vaccine developed by Oxford University and AstraZeneca for temporary supply.

“We have formally asked the regulator to assess the Oxford/AstraZeneca vaccine, to understand the data and determine whether it meets rigorous safety standards,” Health Minister Matt Hancock said in a statement.

“This letter is an important step towards deploying a vaccine as quickly as safely possible.”

Questions have been raised though about the robustness of the trial's results, which showed the vaccine could be 90% effective when given as a half dose followed by a full dose. AstraZeneca said the half dose was approved by independent data safety monitors and the UK regulator, adding that the regulator publicly confirmed there was “no concern”.

Loading...
Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:
COVID-19Global Health
Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Winding down COVAX – lessons learnt from delivering 2 billion COVID-19 vaccinations to lower-income countries

Charlotte Edmond

January 8, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum